#TannerPharma partners with Agenus to expand access to botensilimab & balstilimab for MSS CRC & other #cancers, offering new opportunities for patients. businesswire.com/news/home/2024…

Don't miss posters by Yelena Y. Janjigian MD, Sam Cytryn, & Steve Maron at ASCO #GI25! They will share updates on clinical trials in progress for people with #gastrointestinalcancer. bit.ly/40VdQJX 11:30 a.m. – 1 p.m. PST | Level 1, West Hall

Incredible work, Dr. Dr. Marwan G. Fakih! BOT +/- BAL showing ORR 19% and DCR 55% in chemoresistant MSS CRC. The durability of these responses is notable! Thank you for your leadership. #GI25 #MSSCRC #Oncology Colorectal Cancer Alliance Fight Colorectal Cancer

🚨 NEW in Journal of Clinical Oncology shows promise for advanced sarcomas Combining #BOT/#BAL: ✅ ORR: 19.2% (all sarcomas) ✅ ORR: 27.8% (angiosarcoma) ✅ Durable responses: 21.7 months median DOR ✅ Manageable safety Kudos to Dr. Breelyn Wilky, MD 🎗 , Agenus & team ascopubs.org/doi/10.1200/JC…

Very excited to see this in print! Such promising outcomes for immune cold #sarcomas with Botensilimab Plus Balstilimab ascopubs.org/doi/10.1200/JC… Agenus CU Cancer Center

Great work Dr. Myriam Chalabi! Enhance T-cell priming and expansion, complement PD-1 , and reinvigorate Ts for broader and deeper responses! You know where to take this next!

And it looks like this 🙌 Beautiful Breelyn Wilky, MD 🎗 Journal of Clinical Oncology #BOTENSILIMAB Jon Trent, MD, PhD #sarcoma

Yes - visionary Pashtoon Kasi MD, MS, look at that➡️➡️➡️Flat curves=longevity! MiNK Therapeutics Agenus #BOTENSILIMAB 🔥💪 #CancerResearch #NEST #UNICORN

HAPPENING SOON: 🚨 MiNK Therapeutics’s Dr. Sam Cytryn & @MSKCC to take the stage tomorrow (Monday) at #AACRIO25 with first of a kind data on iNKT cell combo in gastric cancer. Stay tuned! 🩸🔥 #CancerImmunotherapy Agenus #Cancer #m

MSS colon cancer has long resisted immunotherapy.; #BOTENSILIMAB is changing this: - 29% pCR in (UNICORN) - 100% RFS at 18.2 mos (NEST) - 19% ORR in r/r mCRC - 71% ORR w/ chemo + targeted Tx in 1L CRC cancerworld.net/botensilimab-a… via CancerWorld Agenus Pashtoon Kasi MD, MS

🧬 What if cancer immunotherapy restored what matters most—IMMUNITY? 📣 TODAY I join ImmunityBio, Inc. to spotlight why immune reconstitution is not just supportive care—it’s the next investable frontier in oncology. 🔥 Because when you rebuild the immune system, you don’t just

Great Pres by Johanna Joyce #AACR25 Prior cancer tx leave fibrotic scars — immune safehouses where dormant tumor cells hide and exhaustion reigns. PV macrophages responding to TGFβ drive. Potential for #INKTs #AGENT797 to break the cycle and reignite immune attack. MiNK Therapeutics

At #AACR25, the always insightful and provocative Dr. Dr Marcela Maus presents unpublished data: IFN-γ/IFN-γR KO CAR-Ts expand and persist better. As genetic modulations evolve, patients—not models—should drive CAR selection. Living medicines are here. Collaboration is key. We need

It was a privilege to celebrate a true giant. Dr. Dan Von Hoff’s remarks remind us that greatness isn’t measured in inches. With humility, truth, and unmatched contributions to science and humanity, he stands among the giants. As Margaret Foti, PhD, MD (hc) said, “His excellence and patient

Amazing data from Myriam Chalabi of NKI on use of Bot/Bal (Agenus) on MMR deficient and proficient tumors! Really impressive neoadjvuant data! AACR #AACR2025

When the “coldest” tumors melt: Myriam Chalabi breaks new ground (again) at #AACR25. NEOASIS Trial: • 80% MPR in dMMR (70% pCR!) • 60% MPR in pMMR BOT/BAL are pushing ICB into non-immunogenic tumors. #CancerImmunotherapy #BOT/BAL

Agenus & Zydus Lifesciences Ltd. announce a $141M partnership to advance BOT/BAL, combining IO innovation with global manufacturing to expand cancer immunotherapy access in India & beyond. Read more: bit.ly/4knAz8u. #ImmunoOncology #GlobalHealth #Manufacturing #CancerResearch